These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 31560772)

  • 1. Reply to Letter to the Editor of Dr. Sitkin et al., Regarding "Altered Sphingolipid Metabolism and its Interaction With the Intestinal Microbiome is Another Key to the Pathogenesis of Inflammatory Bowel Disease".
    Daniluk U; Daniluk J; Ciborowski M
    Inflamm Bowel Dis; 2019 Nov; 25(12):e159. PubMed ID: 31560772
    [No Abstract]   [Full Text] [Related]  

  • 2. Altered Sphingolipid Metabolism and its Interaction With the Intestinal Microbiome Is Another Key to the Pathogenesis of Inflammatory Bowel Disease.
    Sitkin S; Demyanova E; Vakhitov T; Pokrotnieks J
    Inflamm Bowel Dis; 2019 Nov; 25(12):e157-e158. PubMed ID: 31560761
    [No Abstract]   [Full Text] [Related]  

  • 3. Inventory of a reservoir: friends & foes.
    Ahuja V
    Indian J Med Res; 2015 Jul; 142(1):4-6. PubMed ID: 26261160
    [No Abstract]   [Full Text] [Related]  

  • 4. Practical Considerations and the Intestinal Microbiome in Disease: Antibiotics for IBD Therapy.
    Fedorak RN; Ismond KP
    Dig Dis; 2016; 34(1-2):112-21. PubMed ID: 26982586
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Intestinal Microbiota in Inflammatory Bowel Disease.
    Becker C; Neurath MF; Wirtz S
    ILAR J; 2015; 56(2):192-204. PubMed ID: 26323629
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Urinary metabolic insights into host-gut microbial interactions in healthy and IBD children.
    Martin FP; Su MM; Xie GX; Guiraud SP; Kussmann M; Godin JP; Jia W; Nydegger A
    World J Gastroenterol; 2017 May; 23(20):3643-3654. PubMed ID: 28611517
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Letter: off-label use of hyperbaric oxygen therapy in inflammatory bowel disease-Authors' reply.
    Simsek M; de Boer NKH
    Aliment Pharmacol Ther; 2020 Jul; 52(1):216-217. PubMed ID: 32529768
    [No Abstract]   [Full Text] [Related]  

  • 8. The role of inflammation in temporal shifts in the inflammatory bowel disease mucosal microbiome.
    Kiely CJ; Pavli P; O'Brien CL
    Gut Microbes; 2018 Nov; 9(6):477-485. PubMed ID: 29543557
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Role of antibiotics for treatment of inflammatory bowel disease.
    Nitzan O; Elias M; Peretz A; Saliba W
    World J Gastroenterol; 2016 Jan; 22(3):1078-87. PubMed ID: 26811648
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Reply to the Letter to the Editor of Drs. Sitkin and Pokrotnieks.
    Delday M; Mulder I; Logan ET; Grant G
    Inflamm Bowel Dis; 2019 May; 25(6):e72. PubMed ID: 30561627
    [No Abstract]   [Full Text] [Related]  

  • 11. Probiotics in Inflammatory Bowel Disease.
    Abraham BP; Quigley EMM
    Gastroenterol Clin North Am; 2017 Dec; 46(4):769-782. PubMed ID: 29173520
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inflammatory bowel disease.
    Casey G
    Nurs N Z; 2017 Mar; 23(2):20-24. PubMed ID: 30556986
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Probiotics for inflammatory bowel diseases: a promising adjuvant treatment.
    Coqueiro AY; Raizel R; Bonvini A; Tirapegui J; Rogero MM
    Int J Food Sci Nutr; 2019 Feb; 70(1):20-29. PubMed ID: 29804478
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Review article: the gut microbiome in inflammatory bowel disease-avenues for microbial management.
    McIlroy J; Ianiro G; Mukhopadhya I; Hansen R; Hold GL
    Aliment Pharmacol Ther; 2018 Jan; 47(1):26-42. PubMed ID: 29034981
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mechanisms of Pediatric Inflammatory Bowel Disease.
    Peloquin JM; Goel G; Villablanca EJ; Xavier RJ
    Annu Rev Immunol; 2016 May; 34():31-64. PubMed ID: 27168239
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Incidence, clinical presentation and location at diagnosis of pediatric inflammatory bowel disease: a prospective population-based study in northern France (1988-1999).
    Auvin S; Molinié F; Gower-Rousseau C; Brazier F; Merle V; Grandbastien B; Marti R; Lerebours E; Dupas JL; Colombel JF; Salomez JL; Cortot A; Turck D
    J Pediatr Gastroenterol Nutr; 2005 Jul; 41(1):49-55. PubMed ID: 15990630
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Letter: smoking as a modifiable risk factor for a complicated course in Crohn's disease. Authors' reply.
    De Bie C; Ferrante M
    Aliment Pharmacol Ther; 2016 Feb; 43(3):441. PubMed ID: 26782115
    [No Abstract]   [Full Text] [Related]  

  • 18. Differences in epidemiological features between ulcerative colitis and Crohn's disease: The early life-programmed versus late dysbiosis hypothesis.
    Beaugerie L; Langholz E; Nyboe-Andersen N; Pigneur B; Sokol H;
    Med Hypotheses; 2018 Jun; 115():19-21. PubMed ID: 29685190
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Search for Causative Environmental Factors in Inflammatory Bowel Disease.
    Rogler G; Zeitz J; Biedermann L
    Dig Dis; 2016; 34 Suppl 1():48-55. PubMed ID: 27548430
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sphingolipids in neutrophil function and inflammatory responses: Mechanisms and implications for intestinal immunity and inflammation in ulcerative colitis.
    Espaillat MP; Kew RR; Obeid LM
    Adv Biol Regul; 2017 Jan; 63():140-155. PubMed ID: 27866974
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.